MPC Therapeutics

Startup

Summarized by Halo AI

MPC Therapeutics is a Swiss biotech company that develops small-molecule metabolic reprogramming tools to enhance the performance, consistency, and durability of CAR-T and other cell therapies.

Founded & HQ

Geneva, Switzerland

Company size

1-10 employees

Funding

~$1.7M

IP status

1 patent filed · 2 grants confirmed

Activity highlights

Launched commercialization of MitoSTEM, a reagent to boost stem cell proliferation in culture, and signed a research collaboration agreement with Brenner in 2024.

University spin-off biotechnology company at the forefront of T-cell metabolism research. By leveraging decades of mitochondrial biology expertise, MPC Therapeutics aims to create adjunct therapies that make adoptive cell treatments like CAR-T more effective and durable.

AI summary generated on Jun 22, 2026

OpenAlex

For general inquiries

Raphael Martinou

CEO

Is this page yours? Boost its visibility

List technologies, facilities, services, or grant collaboration opportunities.

MPC Therapeutics

For general inquiries

Key links